osteoporosis
Conditions
Interventions
Denosumab group:Denosumab+calcium + vitamin D
bisphosphonates group:bisphosphonates+calcium + vitamin D
Control group:calcium + vitamin D
Sponsors
Department of Orthopedics, Peking University First Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients with reduced bone mass and suffering from MIDLIF for lumbar degenerative diseases in our hospital from May 2021 to October 2022. (1) Aged >= 40 years, and the bone mineral density of the vertebral body or the femoral neck (BMD) measured by dual-energy X-ray absorption method (T value <= -1.0) indicates osteopenia or osteoporosis; (2) Patients treated with MIDLIF for lumbar spinal stenosis, lumbar disc herniation, degenerative lumbar spondylolisthesis, and degenerative spinal deformity.
Exclusion criteria
Exclusion criteria: 1.Preoperative application of anti-osteoporosis drugs; 2.Hormone-induced osteoporosis caused by long-term use of glucocorticoids; 3.Revision surgery after previous lumbar spine surgery; 4.Pathological conditions such as lumbar trauma, tumor or infection; 5.Contraindications related to the use of anti-osteoporosis drugs: hypocalcemia; Renal insufficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fusion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| bone metabolic markers;Osteoporosis related complications; | — |
Countries
China
Contacts
Public ContactSun Haolin
Peking University First Hospital
Outcome results
None listed